Howard Sandler, MD, MS, FASTRO, chair, Radiation Oncology, Ronald H. Bloom Family Chair in Cancer Therapeutics, from Cedars-Sinai, discusses results from a phase III study on docetaxel with hormonal and radiation therapy in prostate cancer.

The RTOG 0521 study randomized patients with high-risk localized prostate cancer to receive six cycles of adjuvant docetaxel with standard hormonal therapy and radiation therapy or hormonal and radiation therapy. An improvement in overall survival (OS) was detected after four years in the docetaxel arm, Sandler explains, with 5% being clinically significant.

OS in the docetaxel arm was 93% and 89% in the arm without docetaxel, Sandler says.

View more from the 2015 ASCO Annual Meeting

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Prostate Cancer

JAN-22-OSD1189 - /clinical/prostate-cancer

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

ASCO Annual Meeting

Howard Sandler, MD, MS, FASTRO, chair, Radiation Oncology, Ronald H. Bloom Family Chair in Cancer Therapeutics, discusses results from a phase III study on docetaxel with hormonal and radiation therapy in prostate cancer.

Dr. Sandler on Docetaxel With Hormonal and Radiation Therapy in Prostate Cancer